AstraZeneca: CHMP Recommends Approval Of Lynparza In Combination With Abiraterone, Prednisone

AstraZeneca PLC (AZN.L,AZN) and MSD's Lynparza in combination with abiraterone and prednisone or prednisolone has been recommended for marketing authorisation in the European Union for the treatment of adult patients with metastatic castration-resistant prostate cancer or mCRPC for whom chemotherapy is not clinically indicated. The CHMP positive opinion was based on results from the PROpel Phase III trial.

Lynparza in combination with abiraterone and prednisone or prednisolone is undergoing priority review in the US for the treatment of mCRPC in adult patients, with a decision expected in fourth quarter, 2022.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing and delivery platform Uber Technologies, Inc. reported Wednesday weak profit in its fourth quarter, while adjusted EBITDA surged from last year with strong revenue growth above market view. Gross bookings increased and the company projects higher gross bookings in the first quarter. Nelson Chai, CFO, said the company significantly exceeded profitability outlook in 2022, ... Societe Generale Group reported Wednesday a weak profit in its fourth quarter, despite higher net banking income. Further, the French Financial services major proposed a dividend and around 440 million euros share buyback program. The company also confirmed fiscal 2025 financial targets. City of Industry, California-based Titans Global Inc. is recalling certain JSJ branded cakes citing potential to contain undeclared eggs, a known allergen, the U.S. Food and Drug Administration said. The recall involves its 95g packages of JSJ Chocolate Cake, JSJ ZSR Cake, and JSJ DMC Leaf Cake food treats.
Follow RTT